Tuberculosis after conversion from azathioprine to mycophenolate mofetil in a long-term renal transplant recipient.

We report the third case in the literature of a patient with a long-lasting renal allograft who experienced tuberculosis just after the switch from azathioprine to mycophenolate mofetil. The switch was likely responsible for the reactivation of dormant tuberculosis; prophylactic antituberculous treatment should be considered in cases of such a therapeutic change.

[1]  K. Budde,et al.  Reactivation of tuberculosis after conversion from azathioprine to mycophenolate mofetil 16 years after renal transplantation. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[2]  P Fauchald,et al.  PLACEBO-CONTROLLED STUDY OF MYCOPHENOLATE MOFETIL COMBINED WITH CYCLOSPORINE AND CORTICOSTEROIDS FOR PREVENTION OF ACUTE REJECTION , 1995 .

[3]  David W. Johnson,et al.  Is mycophenolate mofetil less safe than azathioprine in elderly renal transplant recipients? , 2002, Transplantation.

[4]  R. Ploeg,et al.  Effects of changing immunosuppressive regimen on the incidence, duration, and viral load of cytomegalovirus infection in renal transplantation: a single center report , 2002, Transplant infectious disease : an official journal of the Transplantation Society.

[5]  R. Wolfe,et al.  Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. , 2000, Transplantation.

[6]  H. Badsha,et al.  Mycobacterium haemophilum infection in an SLE patient on mycophenolate mofetil , 2002, Lupus.

[7]  B. Morgenstern,et al.  Disseminated varicella infection in pediatric renal transplant recipients treated with mycophenolate mofetil. , 1999, Transplantation.

[8]  Nina Singh,et al.  Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  P. Halloran,et al.  Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. , 1997, Transplantation.

[10]  J. Wetzels,et al.  Nephrology Dialysis Transplantation the Influence of Mycophenolate Mofetil on the Incidence and Severity of Primary Cytomegalovirus Infections and Disease after Renal Transplantation , 2022 .

[11]  C. van Walraven,et al.  Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. , 2003, Journal of the American Society of Nephrology : JASN.

[12]  M. Burdelski,et al.  B‐cell dysfunction and depletion using mycophenolate mofetil in a pediatric combined liver and kidney graft recipient , 2001, Pediatric transplantation.

[13]  G. Remuzzi,et al.  A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. , 1996, Transplantation.

[14]  M. M. Rees,et al.  Mycophenolate mofetil in cadaveric renal transplantation , 1999 .

[15]  C. Payá,et al.  Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients , 2000, Clinical transplantation.

[16]  M. Klinger,et al.  Mycophenolate mofetil severely depresses antibody response to CMV infection in early posttransplant period. , 2003, Transplantation proceedings.

[17]  J. Squifflet,et al.  DOSE OPTIMIZATION OF MYCOPHENOLATE MOFETIL WHEN ADMINISTERED WITH A LOW DOSE OF TACROLIMUS IN CADAVERIC RENAL TRANSPLANT RECIPIENTS , 2001, Transplantation.

[18]  P. Moreau,et al.  Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients , 2002, Bone Marrow Transplantation.

[19]  R. Atkins,et al.  Laboratory assessment of immune function in renal transplant patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  N. Smedira,et al.  Significant post‐transplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? , 2000, Transplant infectious disease : an official journal of the Transplantation Society.

[21]  A. Ganser,et al.  Increased risk of complicated CMV infection with the use of mycophenolate mofetil in allogeneic stem cell transplantation , 2002, Bone Marrow Transplantation.

[22]  B. Meyers.  Mycobacterium tuberculosis infection in solid organ transplant recipients. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. Poropatich,et al.  Hospitalizations for cytomegalovirus disease after renal transplantation in the United States. , 2002, Annals of epidemiology.